BioSig Technologies, Inc.Highlights Use Of PURE EP Platform By Researchers For 'real-time tissue-specific feedback to achieve equal lesion quality and dimension in a third of the time as conventional methods that rely on surrogate metrics'
Portfolio Pulse from Benzinga Newsdesk
BioSig Technologies' PURE EP platform has been used by researchers to achieve equal lesion quality and dimension in a third of the time compared to conventional methods.
May 19, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioSig Technologies' PURE EP platform demonstrates improved efficiency in lesion treatment, potentially increasing demand for the product.
The article highlights the successful use of BioSig Technologies' PURE EP platform by researchers to achieve equal lesion quality and dimension in a third of the time compared to conventional methods. This demonstrates the platform's efficiency and effectiveness, which could lead to increased demand for the product and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100